Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to ...

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, VH184 and VH499.

Some African nations have teams that provide door-to-door health checkups, but HIV testing and drugs are often only available at clinics.

Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

A new study led by researchers from the CUNY Institute for Implementation Science in Population Health (ISPH) finds that the ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...

While there are fewer men living with HIV than women, data shows that more men die of Aids. Experts and organisations ...

The Philadelphia HIV Resource Finder allows Philadelphians to search for treatment and prevention resources throughout the city.